Literature DB >> 31056746

A mutant MATR3 mouse model to explain multisystem proteinopathy.

Xiao Zhang1, Satoshi Yamashita1, Kentaro Hara1, Tsukasa Doki1, Nozomu Tawara1, Tokunori Ikeda1,2, Yohei Misumi1, Ziwei Zhang1, Yoshimasa Matsuo1, Makiko Nagai3, Takashi Kurashige4,5, Hirofumi Maruyama5, Yukio Ando1.   

Abstract

Mutations in the Matrin 3 (MATR3) gene have been identified as a cause of amyotrophic lateral sclerosis (ALS) or vocal cord and pharyngeal weakness with distal myopathy (VCPDM). This study investigated the mechanism by which mutant MATR3 causes multisystem proteinopathy (MSP) including ALS and VCPDM. We first analyzed the muscle pathology of C57BL/6 mice injected with adeno-associated viruses expressing human WT or mutant (S85C) MATR3. We next generated transgenic mice that overexpress mutant (S85C) MATR3, driven by the CMV early enhancer/chicken β-actin promoter, and evaluated their clinicopathological features. Intramuscular injection of viruses expressing WT and mutant MATR3 induced similar myogenic changes, including smaller myofibers with internal nuclei, and upregulated p62 and LC3-II. Mutant MATR3 transgenic mice showed decreased body weight and lower motor activity. Muscle histology demonstrated myopathic changes including fiber-size variation, internal nuclei and rimmed vacuoles. Spinal cord histology showed a reduced number of motor neurons, and activation of microglia and astrocytes. Comprehensive proteomic analyses of muscle demonstrated upregulation of proteins related to chaperones, stress response, protein degradation, and nuclear function. Overexpression of WT and mutant MATR3 similarly caused myotoxicity, recapitulating the clinicopathological features of MSP. These models will be helpful for analyzing MSP pathogenesis and for understanding the function of MATR3.
© 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Matrin 3; adeno-associated virus; amyotrophic lateral sclerosis; multisystem proteinopathy; transgenic mice; vocal cord and pharyngeal weakness with distal myopathy

Mesh:

Substances:

Year:  2019        PMID: 31056746     DOI: 10.1002/path.5289

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Modelling amyotrophic lateral sclerosis in rodents.

Authors:  Tiffany W Todd; Leonard Petrucelli
Journal:  Nat Rev Neurosci       Date:  2022-03-08       Impact factor: 34.870

Review 2.  Complexity and Specificity of Sec61-Channelopathies: Human Diseases Affecting Gating of the Sec61 Complex.

Authors:  Mark Sicking; Sven Lang; Florian Bochen; Andreas Roos; Joost P H Drenth; Muhammad Zakaria; Richard Zimmermann; Maximilian Linxweiler
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

Review 3.  Matrin 3 in neuromuscular disease: physiology and pathophysiology.

Authors:  Ahmed M Malik; Sami J Barmada
Journal:  JCI Insight       Date:  2021-01-11

Review 4.  Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.

Authors:  Tiziana Bonifacino; Roberta Arianna Zerbo; Matilde Balbi; Carola Torazza; Giulia Frumento; Ernesto Fedele; Giambattista Bonanno; Marco Milanese
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

5.  Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology.

Authors:  Macy L Sprunger; Ken Lee; Brian S Sohn; Meredith E Jackrel
Journal:  iScience       Date:  2022-02-11

6.  Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis.

Authors:  Yuan Chao Xue; Chen Seng Ng; Pinhao Xiang; Huitao Liu; Kevin Zhang; Yasir Mohamud; Honglin Luo
Journal:  Front Mol Neurosci       Date:  2020-05-29       Impact factor: 5.639

7.  Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred.

Authors:  Sara Saez-Atienzar; Clifton L Dalgard; Jinhui Ding; Adriano Chiò; Camile Alba; Dan N Hupalo; Matthew D Wilkerson; Robert Bowser; Erik P Pioro; Richard Bedlack; Bryan J Traynor
Journal:  Neurology       Date:  2020-10-19       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.